Empowered Patient Podcast

Dr. Hing Wong is the Founder and CEO of HCW Biologics and a pioneer in the field of inflammaging which recognizes that as we age, chronic inflammation can trigger a range of age-related diseases. Their proprietary platform TOBI is using a unique Tissue FactOr-Based Scaffold to build multifunctional fusion molecules to put a variety of immunotherapeutic molecules together in a drug using subcutaneous injection.

Hing explains, "There is a lot of really strong scientific evidence demonstrating that when we get old, we basically accumulate chronic inflammation. This chronic inflammation with aging basically makes up the word inflammaging. What it does is the accumulation of chronic inflammation and is the cause of a lot of major diseases in humans, such as cancer, neurodegenerative disease, Alzheimer's disease, Parkinson's disease also diabetes. So our mission is to try to find drugs, immunotherapeutic in particular, to disrupt this inflammaging in a sense to disrupt the chronic inflammation accumulation during the aging process."

"Our idea is to get rid of these chronic inflammation sources induced by chemotherapy. So, on the one hand, you can enhance the chemotherapy's efficacy against cancer and also can completely eliminate the side effects caused by the chemotherapy. So that's another reason we chose cancer being our first indication."

#HCW #Inflammaging #Aging #Longevity #HealthSpan #LifeSpan

HCWbiologics.com

Listen to the podcast here

Dr. Hing Wong is the Founder and CEO of HCW Biologics and a pioneer in the field of inflammaging which recognizes that as we age, chronic inflammation can trigger a range of age-related diseases. Their proprietary platform TOBI is using a unique Tissue FactOr-Based Scaffold to build multifunctional fusion molecules to put a variety of immunotherapeutic molecules together in a drug using subcutaneous injection.

Hing explains, "There is a lot of really strong scientific evidence demonstrating that when we get old, we basically accumulate chronic inflammation. This chronic inflammation with aging basically makes up the word inflammaging. What it does is the accumulation of chronic inflammation and is the cause of a lot of major diseases in humans, such as cancer, neurodegenerative disease, Alzheimer's disease, Parkinson's disease also diabetes. So our mission is to try to find drugs, immunotherapeutic in particular, to disrupt this inflammaging in a sense to disrupt the chronic inflammation accumulation during the aging process."

"Our idea is to get rid of these chronic inflammation sources induced by chemotherapy. So, on the one hand, you can enhance the chemotherapy's efficacy against cancer and also can completely eliminate the side effects caused by the chemotherapy. So that's another reason we chose cancer being our first indication."

#HCW #Inflammaging #Aging #Longevity #HealthSpan #LifeSpan

HCWbiologics.com

Download the transcript here

Joško Bobanović is a Partner, Industrial Biotechnology funds at Sofinnova Partners, a leading European venture capital firm in the life sciences. The focus of this group is finding companies that are applying the mature tools that were initially developed for healthcare into industrial disciplines, specifically, applications in food, chemicals, agriculture, and materials.

Joško explains, "In the 20 years from then to now, we have shaved multiple zeros from the cost of sequencing. That's equally true for other areas of biotechnology. That shift has allowed us to open up the application from what we tend to call red biotech, red coming from the blood, in terms of healthcare, to other angles of biotech."

"They often come in color-coded. You have the white biotech, green biotech, and blue biotech. The white one is industrial applications or products that are produced in the chemical industry. Then you have the green biotech, which focuses on and deals with plants. Then you have the blue biotech, which is oriented towards the ocean and typically focuses on algae and similar things. That's kind of how we look at biotech opportunities beyond just healthcare."

@SofinnovaVC #SofinnovaPartners #IndustrialBiotechnology #IndustrialBiotech #DNAScript #Sustainability #Environmentalimpact

sofinnovapartners.com

Listen to the podcast here

Joško Bobanović is a Partner, Industrial Biotechnology funds at Sofinnova Partners, a leading European venture capital firm in the life sciences. The focus of this group is finding companies that are applying the mature tools that were initially developed for healthcare into industrial disciplines, specifically, applications in food, chemicals, agriculture, and materials.

Joško explains, "In the 20 years from then to now, we have shaved multiple zeros from the cost of sequencing. That's equally true for other areas of biotechnology. That shift has allowed us to open up the application from what we tend to call red biotech, red coming from the blood, in terms of healthcare, to other angles of biotech."

"They often come in color-coded. You have the white biotech, green biotech, and blue biotech. The white one is industrial applications or products that are produced in the chemical industry. Then you have the green biotech, which focuses on and deals with plants. Then you have the blue biotech, which is oriented towards the ocean and typically focuses on algae and similar things. That's kind of how we look at biotech opportunities beyond just healthcare."

@SofinnovaVC #SofinnovaPartners #IndustrialBiotechnology #IndustrialBiotech #DNAScript #Sustainability #Environmentalimpact

sofinnovapartners.com

Download the transcript here

Tzvia Bader is the CEO and Co-Founder of TrialJectory which is an Ai-powered tech platform that matches cancer patients with the right clinical trials for their exact diagnosis. TrialJectory also gives pharmaceutical companies and CROs access to patient insights to allow them to effectively design and recruit for clinical trials.

Tzvia explains, "TrialJectory can really be the place where you can easily see all your options, understand all your options, and act upon your options. And by that remove barriers that exist today in patient access to clinical trials and patient access to the most advanced precision offering that exists today for cancer patients."

"I think it's taking some things that have been partially provided, not integrated, and also taking it to the next level of really using smart technology and leveraging it to really personalize it and help and make it relevant and to the patient themselves."

#Cancer #PatientChampion #CancerCare #CancerTreatment #CancerJourney #ClinicalTrials #AI #AIPlatform #DiversityinClinicalTrials

TrialJectory.com

Listen to the podcast here

Tzvia Bader is the CEO and Co-Founder of TrialJectory which is an Ai-powered tech platform that matches cancer patients with the right clinical trials for their exact diagnosis. TrialJectory also gives pharmaceutical companies and CROs access to patient insights to allow them to effectively design and recruit for clinical trials.

Tzvia explains, "TrialJectory can really be the place where you can easily see all your options, understand all your options, and act upon your options. And by that remove barriers that exist today in patient access to clinical trials and patient access to the most advanced precision offering that exists today for cancer patients."

"I think it's taking some things that have been partially provided, not integrated, and also taking it to the next level of really using smart technology and leveraging it to really personalize it and help and make it relevant and to the patient themselves."

#Cancer #PatientChampion #CancerCare #CancerTreatment #CancerJourney #ClinicalTrials #AI #AIPlatform #DiversityinClinicalTrials

TrialJectory.com

Download the transcript here

Dr. Nick West is the Chief Medical Officer and DVP, Global Medical Affairs in Vascular for Abbott and is back on the podcast to talk about their Beyond Intervention global research. This second annual survey looks at hurdles in the patient journey to see where improvements can be made in the patient experience.

Nick explains, "So the year two survey, again, global survey, we went to 13 different geographies, conducted nearly 2000 interviews, half of which with patients, about a quarter with physicians, and then probably slightly less with healthcare leaders or administrators. And we really focused on that upstream portion of the patient journey, from people becoming patients, the awareness and development of symptoms, how that led to interfacing with healthcare, and then diagnostic testing."

"The uncomfortable truth is that patients simply are not getting a good experience. If we look at patients with coronary disease or peripheral arterial disease, there is a huge disconnect between the quality of care that both physicians and healthcare administrators think they're providing and what the patients perceive they are achieving. And we see that for both groups, but there's even more of a disconnect for patients with peripheral arterial disease."

@AbbottCardio #ClinicalTrials #VascularDisease #PAD #PeripheralArteryDisease #CAD #CoronaryArteryDisease #PatientJourney

Abbott.com

Listen to the podcast here

Dr. Nick West is the Chief Medical Officer and DVP, Global Medical Affairs in Vascular for Abbott and is back on the podcast to talk about their Beyond Intervention global research. This second annual survey looks at hurdles in the patient journey to see where improvements can be made in the patient experience.

Nick explains, "So the year two survey, again, global survey, we went to 13 different geographies, conducted nearly 2000 interviews, half of which with patients, about a quarter with physicians, and then probably slightly less with healthcare leaders or administrators. And we really focused on that upstream portion of the patient journey, from people becoming patients, the awareness and development of symptoms, how that led to interfacing with healthcare, and then diagnostic testing."

"The uncomfortable truth is that patients simply are not getting a good experience. If we look at patients with coronary disease or peripheral arterial disease, there is a huge disconnect between the quality of care that both physicians and healthcare administrators think they're providing and what the patients perceive they are achieving. And we see that for both groups, but there's even more of a disconnect for patients with peripheral arterial disease."

@AbbottCardio #ClinicalTrials #VascularDisease #PAD #PeripheralArteryDisease #CAD #CoronaryArteryDisease #PatientJourney

Abbott.com

Download the transcript here

Dr. Dan Gold is the President and CEO of MEI Pharma and is tackling non-Hodgkin's B cell lymphoma to bring a therapy to patients minimizing the toxicities that are associated with current treatments. Their drug candidate zandelisib is a P13K delta inhibitor. It is being studied in lymphoma in B cells to determine if this is a way to block signaling and diminish the malignant capacity of the B cell.

Dan explains, "We sort of think of lymphoma in two flavors. it's either a more chronic disease, or it's a more aggressive disease, and then there is sort of a spectrum that spans that. In the less aggressive, we call it indolent diseases, the patients will live with these cancers for many, many years. "

"So for the cancers that we treat most commonly or that we're studying most commonly, they're more of the indolent variety. It is interesting because the fact that it's indolent, the patients will respond to therapies. But, eventually, the efficacy of that therapy will wane, and they'll need something else. But there are a number of options that can be staged over the years, again, to keep that cancer at bay, or at least minimally invasive and minimally problematic for many, many years. That's the area that we're focusing all of our energies on currently."

"What we have done, and what we have strived to do is to diminish those toxicities so that the patient will stay on the drug as long as possible. So what we've kind of pioneered for this class of drugs, because of the properties of zandelisib, is that we initially give the patient the drug on a daily basis for a couple of months to get that tumor at bay and shrink it as much as we can."

@MEI_Pharma $MEIP #Lymphoma #BloodCancer #P13K #P13KDelta #OptimizedDosing #SanDiego

meipharma.com

Listen to the podcast here

Dr. Dan Gold is the President and CEO of MEI Pharma and is tackling non-Hodgkin's B cell lymphoma to bring a therapy to patients minimizing the toxicities that are associated with current treatments. Their drug candidate zandelisib is a P13K delta inhibitor. It is being studied in lymphoma in B cells to determine if this is a way to block signaling and diminish the malignant capacity of the B cell.

Dan explains, "We sort of think of lymphoma in two flavors. it's either a more chronic disease, or it's a more aggressive disease, and then there is sort of a spectrum that spans that. In the less aggressive, we call it indolent diseases, the patients will live with these cancers for many, many years. "

"So for the cancers that we treat most commonly or that we're studying most commonly, they're more of the indolent variety. It is interesting because the fact that it's indolent, the patients will respond to therapies. But, eventually, the efficacy of that therapy will wane, and they'll need something else. But there are a number of options that can be staged over the years, again, to keep that cancer at bay, or at least minimally invasive and minimally problematic for many, many years. That's the area that we're focusing all of our energies on currently."

"What we have done, and what we have strived to do is to diminish those toxicities so that the patient will stay on the drug as long as possible. So what we've kind of pioneered for this class of drugs, because of the properties of zandelisib, is that we initially give the patient the drug on a daily basis for a couple of months to get that tumor at bay and shrink it as much as we can."

@MEI_Pharma $MEIP #Lymphoma #BloodCancer #P13K #P13KDelta #OptimizedDosing #SanDiego

meipharma.com

Download the transcript here